Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review

Table 5 Current mTOR inhibitor and immune therapy trials for MIBC*

Institution	Regimen	Setting	Trial description	Status	Trial ID
UTHSCSA	Sirolimus	Neoadjuvant	Phase 0 trial for preoperative treatment. Tissue evaluated before and after treatment.	Recruiting	NCT01827618
Hoosier oncology group	Everolimus +/− Paclitaxel	Unspecified^	Phase II trial for Cisplatin ineligible patients. Not a perioperative specific study.	Recruiting	NCT01215136
University of Washington	Sirolimus + GC	Unspecified^	Phase I/II trial for disease of any stage. Patients likely will undergo cystectomy.	Ongoing	NCT01938573
MDACC	INF-alpha	Prior to Biopsy	Phase 1 trial with TURBT conducted following treatment. Radical cystectomy may follow.	Ongoing	NCT00082719

GC = Gemcitabine + Cisplatin. UTHSCSA = The University of Texas Health Science Center at San Antonio. MDACC = M.D. Anderson Cancer Center. TURBT = Transurethral Resection of Bladder Tumor.
*Table does not include trials for multiple solid tumors that may include bladder cancer as a subset.
^Unspecified regimens can be given in the neoadjuvant, adjuvant, locally recurrent, or metastatic setting.

ISSN: 1471-2407